Advanced Biomed Inc. AdVB, set the terms for its initial offering. The Taiwanese biotechnology company, which focuses on cancer treatment, is seeking to raise $125 million. The company has announced that it will be offering up to 25.0 million shares at a price of between $4 and $5 per share. This pricing could value the company up to $625 millions. Univest Securities, the underwriter for the IPO, is expected to list the stock on the Nasdaq under the ticker “ADVB”. The company’s nine-month period ending March 31, 2023 saw a loss on revenue of $1.33m, compared to a loss on revenue of $2.05m a year earlier. The company wants to go public during a period of high investor interest for IPO shares. For example, the Renaissance IPO exchange traded fund has gained 24.9% in the last three months, while the S&P500 SPX +0.71% is up 9.6%.